Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 13/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409099 | 0.91 | PARP1 (0.65) | PARP1KCNH2PARP2HTR6SIGMAR1 | |
| SCHEMBL6405735 | 0.89 | PARP1 (0.85) | PARP1KCNH2PARP2SIGMAR1 | |
| SCHEMBL6405272 | 0.87 | PARP1 (0.85) | PARP1KCNH2PARP2SIGMAR1 | |
| SCHEMBL6407850 | 0.81 | PARP1 (1.00) | PARP1 | |
| SCHEMBL6408260 | 0.79 | PARP1 (1.00) | PARP1DRD2SIGMAR1HTR1A | |
| SCHEMBL6406376 | 0.78 | PARP1 (0.81) | PARP1SIGMAR1HTR1A | |
| SCHEMBL23302831 | 0.75 | PARP1 (0.58) | PARP1KCNH2PARP2DRD2SIGMAR1 | |
| SCHEMBL29882436 | 0.75 | PARP1 (0.58) | PARP1KCNH2PARP2DRD2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6403678 | 0.73 | PARP1 (0.55) | PARP1KCNH2PARP2HTR6SIGMAR1 | |
| SCHEMBL6619881 | 0.73 | DRD2 (0.52) | PARP1KCNH2PARP2HTR6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | PARP1 1/4885KCNH2 2357/4885PARP2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.